EP1335712A2 - Structure de support multicouche pour systemes therapeutiques transdermiques renfermant une substance active - Google Patents

Structure de support multicouche pour systemes therapeutiques transdermiques renfermant une substance active

Info

Publication number
EP1335712A2
EP1335712A2 EP01993461A EP01993461A EP1335712A2 EP 1335712 A2 EP1335712 A2 EP 1335712A2 EP 01993461 A EP01993461 A EP 01993461A EP 01993461 A EP01993461 A EP 01993461A EP 1335712 A2 EP1335712 A2 EP 1335712A2
Authority
EP
European Patent Office
Prior art keywords
active substance
skin
plaster
active ingredient
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01993461A
Other languages
German (de)
English (en)
Inventor
Detlev Radloff
Andreas Schabert
Matthias Wasner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Publication of EP1335712A2 publication Critical patent/EP1335712A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer

Definitions

  • the present invention relates to the execution of a carrier material for active substance-containing plaster systems, generally called transdermal therapeutic systems (TTS).
  • TTS transdermal therapeutic systems
  • TTS Transdermal therapeutic systems
  • This dosage form realizes first-order release kinetics of the active substance, whereby a constant active substance level in the organism can be maintained over a very long period of time.
  • the gastrointestinal tract and the first passage through the liver are avoided through the skin's absorption pathway.
  • selected drugs can be administered effectively in a small dose. This is particularly advantageous when a local action of the drug while avoiding a systemic action is desired. This is the case, for example, in the treatment of rheumatic joint complaints or muscle inflammation.
  • transdermal systems which is well described in the specialist literature is represented by matrix systems or monolithic systems in which the medicament is incorporated directly into the pressure-sensitive pressure sensitive adhesive.
  • a pressure-sensitive, active ingredient-containing matrix is provided on one side with an anti-adhesive release film in the ready-to-use product, which is removed before application to the skin.
  • a carrier film On the opposite side there is a carrier film, the one is an integral part of the system and remains on the plaster during application (adhesive & seal, No. 42, 1998, pp. 26-30).
  • This carrier film of a transdermal therapeutic system has very special requirements.
  • the material used must have sufficient flexibility and elasticity to ensure sufficient patient comfort. If the carrier film used is too rigid, the patient experiences an uncomfortable feeling of foreign bodies. In addition, when applied to moving body regions, an insufficiently elastic carrier material can lead to the detachment of parts or even of the entire product. This would prevent the transport of active substances through the skin and the effectiveness of the TTS is questioned.
  • the storage period here denotes the period between the manufacture of the product and the application to the patient.
  • the maximum time frame is often defined by the shelf life, which is generally three years. From this long period it becomes clear that the material used must represent a very good barrier to the active ingredient and the auxiliary agents used.
  • barrier materials are not very flexible and elastic.
  • Known flexible and elastic carrier materials are generally distinguished by a very low barrier effect against migratable molecules.
  • Carrier materials for plaster systems play an important role above all in wound care. In these applications, the focus is on the comfort of the patient, in particular injuries to strongly moved joints such as in the knee and elbow area or to the hand. In the past, the materials used here were often very soft PVC films that were slowly being replaced by polyolefin films. Modern products are often equipped with a non-woven backing.
  • EP 0 749 756 A2 describes, for example, a nonwoven fabric based on polyester elastomers as a carrier material for a plaster for wound care. Due to the excellent elasticity and conformability of this material, a high degree of comfort is achieved. This is further increased by the property of the strong water vapor permeability of the carrier described.
  • nonwovens are characterized by a microporous structure that contradicts a good barrier effect.
  • migratable ingredients in a plaster system can evaporate very quickly. For this reason, it is not possible to use such a system in the area of the active substance-containing plasters.
  • PET polyethylene terephthalate
  • PET is unsuitable as a carrier material due to its low flexibility and elasticity, even though it is very widespread as such due to the lack of alternatives.
  • this is also due to the fact that conventional active substance-containing plasters are kept very small in size.
  • the location of the dermal application plays a subordinate role in the case of systemically active drugs, which is why the plaster can be applied in the area of the very little moved body regions.
  • the chest area is particularly worth mentioning here.
  • WO 99/12529 A1 describes a compromise between comfort and ease of processing.
  • a unidirectionally elastic support is used here. This makes it possible to use a material that is rigid in the direction of processing, which gives significant advantages during the manufacturing process. However, due to the elasticity perpendicular to this direction, an acceptable level of comfort is achieved. However, the problem of barrier effects is not mentioned.
  • WO 98/29143 A1 describes a very smooth plaster.
  • a carrier material is used here, which is removed after application to the skin.
  • the carrier material to be removed is called the “support layer”.
  • the adhesive layer underneath is provided with an anti-adhesive layer in order to prevent it from sticking to clothing. This results in an extremely thin and therefore highly flexible product structure.
  • disadvantages to this embodiment The processability of such a system and the manageability of the patient. The absence of a carrier during application leads to a significantly more difficult removal of the plaster after use.
  • Adhesives used generally do not have the necessary cohesiveness to the plaster in one piece after wearing
  • the plaster is very sensitive to mechanical stress during wear, for example due to friction with clothing, and no solution is provided, such as the necessary support film on a non-sticky surface layer sticks.
  • the object of the invention is to provide an active substance-containing plaster, the carrier of which has a sufficient barrier effect and which avoids the disadvantages known from the prior art. It should be inexpensive to manufacture and ecologically harmless, and it should also be comfortable to use offer and harmonize the above-mentioned basic requirements for a carrier of a TTS.
  • the invention relates to an active substance-containing plaster with a laminate which is coated on its skin-facing side with an adhesive composition containing an active substance, the laminate having at least two layers.
  • the side facing the active substance-containing adhesive consists ideally of a conformable and elastic material, the side facing away from the adhesive consists of a barrier layer.
  • the bond between the two layers is strong enough on the one hand to remain stable during processing and storage, but on the other hand the bond is labile enough to be separated before or shortly after application to the skin. This removes the barrier layer that is no longer necessary during application and the flexible carrier remains on the plaster.
  • the product according to the invention is very well protected against external influences. For example, depending on the corresponding version, bathing or showering is possible during the application.
  • the remaining flexible carrier film also ensures easy detaching in one piece.
  • polymer films which have a very good barrier effect against aromas due to their microstructure
  • films based on partially crystalline polymers such as polyethylene terephthalate and / or its derivatives as well as polyamides and polyimides
  • films based on halogenated polymers e.g. polyvinyl chloride (PVC) and polyvinylidene chloride (PVDC).
  • the barrier layer is therefore films based on polyamide, polyimide, polyethylene terephthalate and / or its derivatives or halogenated polymers.
  • the barrier layer is applied to the carrier layer by a chemical or physical process.
  • polymer films and papers that are modified by means of metal vapor deposition or metal coating, for example with aluminum, or by means of a coating of metal oxides, such as SiO x or AIO x .
  • the backing layer is preferably a polyolefin film based on ethylene or propylene, optionally produced conventionally or using metallocene catalysis, nonwovens or knitted fabrics which in particular consist of polyester, polyamides, viscose or cotton and their laminates.
  • the application weight of the adhesive on the plaster is in particular in a range from 100 to 500 g / m 2 , particularly preferably 300 g / m 2 .
  • the adhesive composition consists of a pressure-sensitive adhesive matrix, which may contain active ingredients.
  • the matrix can be free from mineral oils and adhesive resins and have the following components: a) synthetic framework polymers based on polyisobutylene at 25 to 90% by weight, b) amorphous poly- ⁇ -olefin at 5 to 40% by weight, c) at least one insoluble, hydrophilic filler with an average grain size of less than 100 microns at 10 to 60 wt .-% and d) optionally a drug at 0.001 to 20 wt .-%.
  • the polyisobutylene is composed of high molecular weight PIB of 5 to 30% by weight and low molecular weight PIB of 20 to 60% by weight.
  • a typical PSA according to the invention thus consists of the following components: high molecular weight PIB 5-30% by weight, preferably 10-20% by weight, low molecular weight PIB 20-60% by weight, preferably 30-50% by weight amorphous poly- ⁇ -olefin 5-30 % By weight preferably 5-20% by weight of hydrophilic filler 20-60% by weight preferably 30-50% by weight optionally pharmaceutical 0.001-20% by weight preferably 1.0-5.0% by weight
  • High molecular weight PIB polyisobutylene with a weight average molecular weight (Mw) of 500,000 to 1100,000, preferably between 650,000 and 850,000.
  • Mw weight average molecular weight
  • Such polymers are commercially available, for example, under the trade names Oppanol B100 (BASF) or Vistanex MM-L80 (Exxon).
  • Low molecular PIB Low molecular PIB:
  • Mw weight average molecular weight
  • Such polymers are commercially available, for example, under the trade names Oppanol B15 (BASF) or Vistanex LMMH (Exxon).
  • Amorphous copolymers based on ethylene and propylene, butylene or 1-hexene are commercially available, for example, under the trade names Eastoflex® (Eastman) or Vestoplast® (Hüls).
  • Hydrophilic filler Hydrophilic particles based on cellulose that are insoluble in the polymer matrix mentioned. An average particle size of less than or equal to 100 ⁇ m with a surface that is as uniform as possible is preferred. Such materials are commercially available, for example, under the trade names Avicel (FMC) and Elcema (Degussa-Hüls).
  • Production is preferably carried out in a process in which all components are homogenized in the melt without the addition of solvents. All components are particularly preferably processed in a continuous or discontinuous process at a temperature below 100.degree.
  • the adhesive is characterized by excellent adhesive properties on the skin, easy and painless releasability, and above all by its extremely low potential to cause skin irritation.
  • the manufacturing process is completely without solvents.
  • Typical active ingredients in the adhesive are - without claiming to be complete in the context of the present invention:
  • hyperemic active ingredients such as natural active ingredients of the cayenne pepper or synthetic active ingredients such as nonivamide, nicotinic acid derivatives, preferably bencyl nicotinate or propyl nicotinate, can also be mentioned.
  • the open adhesive side of the patch to be applied to the skin can be covered with a removable, covering protective layer.
  • a conventional wound dressing can also be arranged on the self-adhesive coating.
  • the patch according to the invention is ideally suited to meet the two main requirements for the carrier system at different times.
  • the wearer During the storage period of the patch, it is essential to ensure that the wearer has a very good barrier effect. Elasticity and flexibility are not required at this point. Rather, the rigidity of a good barrier layer leads to additional protection against mechanical stress during transport, for example during transport. If the product is now applied to the patient, the barrier effect of the backing layer is no longer necessary. Compared to the storage time, the application period of up to 24 hours only plays a subordinate role. However, the flexibility and elasticity of the backing material become important during application.
  • the embodiment of a patch according to the invention reliably prevents the active ingredient from migrating out of the patch system beyond the period of storage until application to the skin.
  • the system according to the invention due to its high flexibility and elasticity, leads to a comfortable fit. This ensures a high level of comfort for the patient and long-term stability of the active substance content.
  • the modulus of elasticity serves as a measure of the elasticity of the film materials.
  • a high modulus of elasticity means low elasticity or flexibility and therefore low wearing comfort.
  • a low modulus of elasticity stands for a material with high elasticity and flexibility and thus for high wearing comfort.
  • the non-steroidal active ingredient ibuprofen is used as an example substance for the permeability of carrier materials.
  • Fraunhofer Institute for Process Engineering and Packaging IVV Order number PA / 4146/99, report from April 28, 2000.
  • Figure 2 Graphical representation of the oxygen permeability of various
  • Laminate in the combination of PET as a carrier material with a high barrier property and a low modulus of elasticity and LDPE as a flexible film with a low barrier effect against active ingredient migration see FIGS. 1 and 2).
  • Laminate in the combination of PET as a carrier material with a high barrier property and a low modulus of elasticity and EVA as a flexible film with a low barrier effect against active ingredient migration see FIGS. 1 and 2).
  • Laminate in the combination of PA 6 as a carrier material with a high barrier property and a low modulus of elasticity and PP as a flexible film with a low barrier effect against active ingredient migration see FIGS. 1 and 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un système thérapeutique transdermique renfermant une substance active. Ce système thérapeutique transdermique comprend un stratifié qui est revêtu sur sa face orientée vers la peau d'une masse adhésive renfermant une substance active. Ce système thérapeutique transdermique est caractérisé en ce que ledit stratifié présente au moins deux couches séparables l'une de l'autre, une couche barrière imperméable à la substance active, située sur la face opposée à la peau, ainsi qu'une couche de support, située sur la face orientée vers la peau.
EP01993461A 2000-11-11 2001-10-31 Structure de support multicouche pour systemes therapeutiques transdermiques renfermant une substance active Withdrawn EP1335712A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10056014 2000-11-11
DE10056014A DE10056014A1 (de) 2000-11-11 2000-11-11 Mehrschichtige Trägerkonstruktion für wirkstofhaltige Pflastersyteme
PCT/EP2001/012602 WO2002038134A2 (fr) 2000-11-11 2001-10-31 Structure de support multicouche pour systemes therapeutiques transdermiques renfermant une substance active

Publications (1)

Publication Number Publication Date
EP1335712A2 true EP1335712A2 (fr) 2003-08-20

Family

ID=7662999

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01993461A Withdrawn EP1335712A2 (fr) 2000-11-11 2001-10-31 Structure de support multicouche pour systemes therapeutiques transdermiques renfermant une substance active

Country Status (5)

Country Link
US (1) US20040091521A1 (fr)
EP (1) EP1335712A2 (fr)
AU (1) AU2002218271A1 (fr)
DE (1) DE10056014A1 (fr)
WO (1) WO2002038134A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087549A (en) * 1997-09-22 2000-07-11 Argentum International Multilayer laminate wound dressing
US7214847B1 (en) * 1997-09-22 2007-05-08 Argentum Medical, L.L.C. Multilayer conductive appliance having wound healing and analgesic properties
US8455710B2 (en) 1997-09-22 2013-06-04 Argentum Medical, Llc Conductive wound dressings and methods of use
US8801681B2 (en) * 1995-09-05 2014-08-12 Argentum Medical, Llc Medical device
US5814094A (en) * 1996-03-28 1998-09-29 Becker; Robert O. Iontopheretic system for stimulation of tissue healing and regeneration
US6861570B1 (en) * 1997-09-22 2005-03-01 A. Bart Flick Multilayer conductive appliance having wound healing and analgesic properties
AU2003254834B2 (en) * 2002-08-09 2009-02-19 Fuso Pharmaceutical Industries, Ltd. Female hormone-containing patch
JP6150240B2 (ja) * 2012-09-21 2017-06-21 東洋製罐株式会社 包装材およびそれを用いてなる包装構造

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4943435A (en) * 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US4994278A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Breathable backing
DE3908431A1 (de) * 1989-03-15 1990-09-27 Lohmann Therapie Syst Lts Transdermales system mit gestufter wirkstoffabgabe und verwendung fuer die lokale oder systemische wirkstoffverabreichung
DE3939376C1 (fr) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5264219A (en) * 1992-08-07 1993-11-23 Minnesota Mining And Manufacturing Company Transdermal drug delivery backing
JPH06183980A (ja) * 1992-12-24 1994-07-05 Sekisui Chem Co Ltd アスピリン含有貼付剤の製造方法
US5567489A (en) * 1993-09-16 1996-10-22 The Dow Chemical Company Multilayer halogen-free barrier film for ostomy and transdermal drug delivery applications
GB9500716D0 (en) * 1995-01-14 1995-03-08 Giltech Ltd Self adhesive laminate
DE19654468C1 (de) * 1996-12-27 1998-01-22 Lohmann Therapie Syst Lts Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung
DE19702314C2 (de) * 1997-01-23 2000-12-21 Lohmann Therapie Syst Lts Ablösbare Schutzfolie für wirkstoffhaltige, insbesondere selbstklebende Pflastersysteme
DE19705138A1 (de) * 1997-02-11 1998-08-13 Lohmann Therapie Syst Lts Dehnbares transdermales therapeutisches System
JPH10234839A (ja) * 1997-02-28 1998-09-08 Kyowa:Kk 生体用貼付材
DE19733981A1 (de) * 1997-08-06 1999-02-11 Lohmann Therapie Syst Lts Transdermales Therapeutisches System (TTS) zur Abgabe von Wirkstoff durch die Haut an einen Organismus und Verfahren zur Applikation auf der Haut
DE19820999A1 (de) * 1998-05-11 1999-11-18 Lohmann Therapie Syst Lts Laminat zum Aufbringen auf einen Akzeptor
DE19943317C1 (de) * 1999-09-10 2001-03-15 Lohmann Therapie Syst Lts Kunststofffolien, insbesondere für die Verwendung in einem dermalen oder transdermalen therapeutischen System und Verfahren zu ihrer Herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0238134A2 *

Also Published As

Publication number Publication date
US20040091521A1 (en) 2004-05-13
AU2002218271A1 (en) 2002-05-21
WO2002038134A3 (fr) 2002-07-18
DE10056014A1 (de) 2002-05-16
WO2002038134A2 (fr) 2002-05-16

Similar Documents

Publication Publication Date Title
DE10212864B4 (de) Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US6072100A (en) Extrudable compositions for topical or transdermal drug delivery
DE60033426T2 (de) Adhäsive zubereitungen
EP0598606A1 (fr) Compositions extrudables pour l'administration topique ou transdermique de médicaments
EP1450773B1 (fr) Systeme therapeutique transdermique a confort de port longue duree ameliore
EP2760436B1 (fr) Pansements à occlusion ajustable
US20020192287A1 (en) Extrudable compositions for topical or transdermal drug delivery
EP1480625B1 (fr) Systeme transdermique au fentanyle
WO2002038134A2 (fr) Structure de support multicouche pour systemes therapeutiques transdermiques renfermant une substance active
WO2002038135A2 (fr) Film barriere flexible pour support destine a des applications medicales
EP2921184A1 (fr) Pansement de recouvrement à tolérance améliorée et longue durée d'adhérence et son procédé de fabrication
DE102004038285A1 (de) Aromatherapie
EP1368008B1 (fr) Systeme therapeutique transdermique pour l'administration d'agoniste partiel de la dopamine d2 aripiprazol
DE102004039728A1 (de) Wirkstoffhaltiges Tape zur Behandlung von Gelenkerkrankungen
DE102006001162A1 (de) Pflasterabdeckung bei atopischer Dermatitis
EP3829550B1 (fr) Systeme thérapeutique transdermique pour l'administration de scopolamine
EP1349544A2 (fr) Autocollant comportant des agents de fluidification de secretions naturelles des voies respiratoires
DE19840191A1 (de) Arzneistoffhaltiges Pflaster mit drei funktionalen Schichten
DE102018216244A1 (de) Transdermales therapeutisches System mit Barriereschicht
WO2014198422A1 (fr) Système thérapeutique transdermique (tts) doté de rotigotine
WO1994005295A1 (fr) Systeme therapeutique percutane contenant du pentylenetetrazol comme principe actif
DE10304988A1 (de) Transdermales Therapeutisches System mit verbessertem Hautklebeverhalten
DE102021128912A1 (de) Okklusives pflaster mit flexibler backing
WO2020109241A1 (fr) Système thérapeutique transdermique comprenant une barrière de diffusion
DE10360592A1 (de) Pflastersystem zur Verabreichung von Antihistaminika

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030611

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: RADLOFF, DETLEV

Inventor name: WASNER, MATTHIAS

Inventor name: SCHABERT, ANDREAS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050503